Elderly people and adults with chronic disease or compromised immune status are at increased risk of pneumococcal infection, with pneumonia being the most common serious presentation and a significant cause of morbidity and mortality. Most European countries have recommendations for pneumococcal vaccination but vaccination rates have remained low. In the present article, the authors present the results of a European survey that investigated the current level of awareness of pneumococcal infection among primary care physicians and specialists, and attitudes to vaccination in these physicians and members of the general public aged >50 years.
Primary care physicians (n = 1,300) and specialists (n = 926) from 13 Western European countries participated in online/face-to-face interviews, and a further 6,534 individuals aged >50 years from a population sample reflecting local socio-demographic structure participated in telephone/face-to-face interviews.
Pneumonia was the most well-known of the pneumococcal infections amongst primary care physicians and specialists. However, there was a relatively low awareness of the term invasive pneumococcal disease (IPD), with only 50% of primary care physicians and 71% of specialists reporting knowledge of the term IPD. Key factors influencing a physician’s decision to prescribe pneumococcal vaccination were the patient’s health condition, recommendations from health authorities, and the tolerability of the vaccine. Perceptions regarding vaccination were good amongst the members of the general public; individuals did not fear vaccines or their side effects. The main drivers for vaccination were recommendations from a healthcare professional and, to a lesser extent, that vaccination provides reassurance against contracting a disease.
These findings highlight the low awareness of the term IPD in comparison with individual pneumococcal conditions. Given the importance of physician recommendations in encouraging patients to be vaccinated, primary care physicians need to be vigilant of patients at risk of pneumococcal infections in order to increase vaccination rates.
Htwe TH, Mushtaq A, Robinson SB, Rosher RB, Khardori N. Infection in the elderly. Infect Dis Clin North Am. 2007;21:711–743, ix.
Liang SY, Mackowiak PA. Infections in the elderly. Clin Geriatr Med. 2007;23:441–456, viii.
Gusmano MK, Michel JP. Life course vaccination and healthy aging. Aging Clin Exp Res. 2009;21:258–263.
Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2:659–666.
Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–79.
Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int. 2009;22:1041–1050.
Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect. 2012;18:7–14.
Sjostrom K, Spindler C, Ortqvist A, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis. 2006;42:451–459.
Reinert RR, Haupts S, van der Linden M, et al. Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001–2003. Clin Microbiol Infect. 2005;11:985–991.
Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729–1735.
Fung HB, Monteagudo-Chu MO. Communityacquired pneumonia in the elderly. Am J Geriatr Pharmacother. 2010;8:47–62.
Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;CD000422.
Siemieniuk RA, Gregson DB, Gill MJ. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis. 2011;11:314.
Yin Z, Rice BD, Waight P, et al. Invasive pneumococcal disease among HIV-positive individuals, 2000–2009. AIDS. 2012;26:87–94.
Grau I, Ardanuy C, Linares J, Podzamczer D, Schulze MH, Pallares R. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease. HIV Med. 2009;10:488–495.
Elston JW, Santaniello-Newton A, Meigh JA, et al. Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake: surveillance in Hull and East Yorkshire, UK, 2002–2009. Epidemiol Infect. 2012;140:1252–1266.
Kyaw MH, Christie P, Clarke SC, et al. Invasive pneumococcal disease in Scotland, 1999–2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis. 2003;37:1283–1291.
Trotter CL, Waight P, Andrews NJ, et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006. J Infect. 2010;60:200–208.
Jansen AG, Rodenburg GD, de Greeff SC, et al. Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine. 2009;27:2394–2401.
Ardanuy C, Tubau F, Pallares R, et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997–2007. Clin Infect Dis. 2009;48:57–64.
Giner AM, Kuster SP, Zbinden R, Ruef C, Ledergerber B, Weber R. Initial management of and outcome in patients with pneumococcal bacteraemia: a retrospective study at a Swiss university hospital, 2003–2009. Infection. 2011;39:519–526.
Fedson DS, Nicolas-Spony L, Klemets P, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines. 2011;10:1143–1167.
Department of Health. Pneumococcal polysaccharide vaccine (PPV) uptake summary report. Available at: http://immunisation.dh.gov.uk/ppv-uptake-report-2012. Accessed Apr 9 2013.
World ESOMAR Research, ICC. ICC/ISOMAR International Code on market and social research. ESOMAR 2007. Available at: http://www.esomar.org/uploads/public/knowledge-and-standards/codes-and-guidelines/ESOMAR_ICC-ESOMAR_Code_English.pdf. Accessed Mar 27 2013.
CNIL. Decree No 2005-1309 of 20 October 2005 enacted for the application of Act No 78-17 of 6 January 1978 on Data Processing, Files and Individual Liberties (Amended by Decree 2007-451 of 25 March 2007) Consolidated on the 25th of March 2007. CNIL 2007. Available at: http://www.cnil.fr/fileadmin/documents/en/Decree%202005-1309._pdf. Accessed Mar 27 2013.
Musher DM. Pneumococcal infections. In: Kasper DL, Fauci AS, eds. Harrison’s Infectious Diseases. McGraw Hill Medical; 2010:374–385.
Bordon J, Peyrani P, Brock GN, et al. The presence of pneumococcal bacteraemia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. Chest. 2008;133:618–624.
Gil-Prieto R, Garcia-Garcia L, Alvaro-Meca A, Mendez C, Garcia A, de Miguel AG. The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003–2007). Vaccine. 2011;29:412–416.
Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax. 2012;67:540–545.
van Mens SP, Meijvis SC, Endeman H, et al. Longitudinal analysis of pneumococcal antibodies during community-acquired pneumonia reveals a much higher involvement of Streptococcus pneumoniae than estimated by conventional methods alone. Clin Vaccine Immunol. 2011;18:796–801.
Gavazzi G, Wazieres B, Lejeune B, Rothan-Tondeur M. Influenza and pneumococcal vaccine coverages in geriatric health care settings in France. Gerontology. 2007;53:382–387.
Martinelli D, Tafuri S, Caputi G, et al. Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: survey on coverage rate among elderly and chronic patients. Am J Infect Control. 2010;38:e8–e15.
Mohseni-Zadeh M, Rey D, Batard ML, et al. Inadequate vaccination coverage in a French cohort of HIV positive patients [In French]. Med Mal Infect. 2010;40:683–690.
Teich N, Klugmann T, Tiedemann A, et al. Vaccination coverage in immunosuppressed patients: results of a regional health services research study. Dtsch Arztebl Int. 2011;108:105–111.
Zimmerman RK, Nowalk MP, Tabbarah M, Hart JA, Fox DE, Raymund M. Understanding adult vaccination in urban, lower-socioeconomic settings: influence of physician and prevention systems. Ann Fam Med. 2009;7:534–541.
Krueger P, St Amant O, Loeb M. Predictors of pneumococcal vaccination among older adults with pneumonia: findings from the Community Acquired Pneumonia Impact Study. BMC Geriatr. 2010;10:44.
Michel JP. Updated vaccine guidelines for aging and aged citizens of Europe. Expert Rev Vaccines. 2010;9:7–10.
Lau D, Hu J, Majumdar SR, Storie DA, Rees SE, Johnson JA. Interventions to improve influenza and pneumococcal vaccination rates among community-dwelling adults: a systematic review and meta-analysis. Ann Fam Med. 2012;10:538–546.
Badertscher N, Morell S, Rosemann T, Tandjung R. General practitioners’ experiences, attitudes, and opinions regarding the pneumococcal vaccination for adults: a qualitative study. Int J Gen Med. 2012;5:967–974.
Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180:48–58.
Foster D, Walker AS, Paul J, et al. Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol. 2011;60:91–97.
Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41.
Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2:e00309–e00310.
Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines. 2010;9:229–236.
Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. Pediatrics. 2008;121:253–260.
Cohen R, Levy C, de La Rocque F, et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006;25:1001–1007.
Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737–1746.
Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043–2051.
Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760–768.
Myint TT, Madhava H, Balmer P, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30:127–151.
Pfizer Limited. Prevenar 13 suspension for injection summary of product characteristics. eMC. Available at: http://www.medicines.org.uk/emc/medicine/22689/SPC/Prevenar+13+suspension+for+injection/. Accessed Feb 4 2013.
European Medicines Agency. Prevenar 13. European Medicines Agency 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001104/smops/Positive/human_smop_000452.jsp&mid=WC0b01ac058001d127. Accessed Mar 4 2013.
GlaxoSmithKline Biologicals s.a. Synoflorix. Summary of product characteristics. European Medicines Agency 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000973/WC500054346.pdf. Accessed Mar 4 2013.
Jackson LA, Gurtman A, van Cleeff M. Immunogenicity and safety of a 13-valent pneumococcal conjugate caccine in pneumococcal vaccine naive adults, 50–64 years of age [abstract O426]. Clin Microbiol Infect. 2011;17:S85.
Jackson LA, Gurtman A, van Cleeff M. 13-valent pneumococcal conjugate vaccine (PCV13) enhances the response to subsequent PCV13 and 23-valent pneumococcal polysaccharide (PPSV23) vaccinations in adults 50 years and older [abstract LB-3]. Presented at the 49th Annual Meeting of the Infectious Diseases Society of America; October 20–23, 2011; Boston, MA.
To view enhanced content go to www.advancesintherapy.com
This article is published with open access at Springerlink.com
Electronic supplementary material
About this article
Cite this article
Lode, H., Ludwig, E. & Kassianos, G. Pneumococcal Infection — Low Awareness as a Potential Barrier to Vaccination: Results of a European Survey. Adv Therapy 30, 387–405 (2013). https://doi.org/10.1007/s12325-013-0025-4
- Infectious diseases
- Invasive pneumococcal disease
- Pneumococcal infection